LUMO insider filings

LUMOS PHARMA, INC. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-12-13. Screen LUMO transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for LUMO between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — LUMOS PHARMA, INC.

FiledFormInsiderReported transactionsSource
2024-12-134Hawkins Richard J — Chief Executive Officer, DirectorDisposition to issuer (D): 753,093 · Disposition to issuer (D): 4,469 · Disposition to issuer (D): 19,624 (derivative) · Disposition to issuer (D): 35,400 (derivative) · Disposition to issuer (D): 35,400 (derivative) · Disposition to issuer (D): 135,000 (derivative) · +2 moreEDGAR
2024-12-134Zoth Lota S. — DirectorDisposition to issuer (D): 2,187 · Disposition to issuer (D): 3,345 (derivative) · Disposition to issuer (D): 3,328 (derivative) · Disposition to issuer (D): 5,684 (derivative) · Disposition to issuer (D): 3,431 (derivative) · Disposition to issuer (D): 2,910 (derivative) · +2 moreEDGAR
2024-12-134McKew John C. — Chief Scientific OfficerDisposition to issuer (D): 13,153 · Disposition to issuer (D): 16,000 (derivative) · Disposition to issuer (D): 16,000 (derivative) · Disposition to issuer (D): 6,541 (derivative) · Disposition to issuer (D): 9,583 (derivative) · Disposition to issuer (D): 81,690 (derivative) · +3 moreEDGAR
2024-12-134JOHNSON CHAD ALLEN — DirectorDisposition to issuer (D): 1,076 · Disposition to issuer (D): 3,345 (derivative) · Disposition to issuer (D): 3,328 (derivative) · Disposition to issuer (D): 5,684 (derivative) · Disposition to issuer (D): 3,431 (derivative) · Disposition to issuer (D): 2,910 (derivative) · +2 moreEDGAR
2024-12-134van Es-Johansson An — DirectorDisposition to issuer (D): 1,100 · Disposition to issuer (D): 3,345 (derivative) · Disposition to issuer (D): 3,328 (derivative) · Disposition to issuer (D): 3,431 (derivative) · Disposition to issuer (D): 2,910 (derivative) · Disposition to issuer (D): 5,729 (derivative)EDGAR
2024-12-134Raffin Thomas A. — DirectorDisposition to issuer (D): 9,406 · Disposition to issuer (D): 3,345 (derivative) · Disposition to issuer (D): 3,328 (derivative) · Disposition to issuer (D): 5,684 (derivative) · Disposition to issuer (D): 3,431 (derivative) · Disposition to issuer (D): 2,910 (derivative) · +2 moreEDGAR
2024-12-134Pitukcheewanont Pisit Duke — Chief Medical OfficerDisposition to issuer (D): 16,836 · Disposition to issuer (D): 3,333 (derivative) · Disposition to issuer (D): 25,500 (derivative) · Disposition to issuer (D): 41,500 (derivative) · Disposition to issuer (D): 29,750 (derivative)EDGAR
2024-12-134LALANDE KEVIN M. — DirectorDisposition to issuer (D): 1,076 · Disposition to issuer (D): 730,446 · Disposition to issuer (D): 3,345 (derivative) · Disposition to issuer (D): 3,328 (derivative) · Disposition to issuer (D): 5,684 (derivative) · Disposition to issuer (D): 3,431 (derivative) · +1 moreEDGAR
2024-12-134Schuchart Aaron — Chief Business OfficerDisposition to issuer (D): 8,179 · Disposition to issuer (D): 12,000 (derivative) · Disposition to issuer (D): 12,000 (derivative) · Disposition to issuer (D): 45,000 (derivative) · Disposition to issuer (D): 12,000 (derivative) · Disposition to issuer (D): 7,805 (derivative) · +1 moreEDGAR
2024-12-134POWERS BRADLEY J — General CounselDisposition to issuer (D): 6,307 · Disposition to issuer (D): 27 · Disposition to issuer (D): 11,000 (derivative) · Disposition to issuer (D): 11,000 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 11,000 (derivative) · +4 moreEDGAR
2024-12-134Lawley Lori D — Chief Financial OfficerDisposition to issuer (D): 12,284 · Disposition to issuer (D): 12,000 (derivative) · Disposition to issuer (D): 12,000 (derivative) · Disposition to issuer (D): 21,250 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 12,000 (derivative) · +4 moreEDGAR
2024-12-134McCracken Joseph S — DirectorDisposition to issuer (D): 15,721 · Disposition to issuer (D): 3,345 (derivative) · Disposition to issuer (D): 3,328 (derivative) · Disposition to issuer (D): 5,684 (derivative) · Disposition to issuer (D): 3,431 (derivative) · Disposition to issuer (D): 2,910 (derivative)EDGAR
2024-08-064McKew John C. — Chief Scientific OfficerSale (S): 3,407 @ $1.89EDGAR
2024-08-054Lawley Lori D — Chief Financial OfficerTax withholding (F): 229 @ $1.79EDGAR
2024-08-054McKew John C. — Chief Scientific OfficerTax withholding (F): 1,593 @ $1.79EDGAR
2024-07-034Pitukcheewanont Pisit Duke — Chief Medical OfficerTax withholding (F): 274 @ $2.26EDGAR
2024-06-074van Es-Johansson An — DirectorGrant/award (A): 3,328 (derivative) @ $0EDGAR
2024-06-074McCracken Joseph S — DirectorGrant/award (A): 3,328 (derivative) @ $0EDGAR
2024-06-074JOHNSON CHAD ALLEN — DirectorGrant/award (A): 3,328 (derivative) @ $0EDGAR
2024-06-074Zoth Lota S. — DirectorGrant/award (A): 3,328 (derivative) @ $0EDGAR
2024-06-074Raffin Thomas A. — DirectorGrant/award (A): 3,328 (derivative) @ $0EDGAR
2024-06-074LALANDE KEVIN M. — DirectorGrant/award (A): 3,328 (derivative) @ $0EDGAR
2024-06-044Pitukcheewanont Pisit Duke — Chief Medical OfficerTax withholding (F): 320 @ $2.25EDGAR
2024-04-034Pitukcheewanont Pisit Duke — Chief Medical OfficerGrant/award (A): 6,000 @ $2.84 · Grant/award (A): 41,500 (derivative) @ $0EDGAR
2024-04-034POWERS BRADLEY J — General CounselGrant/award (A): 900 @ $2.84 · Tax withholding (F): 342 @ $2.84 · Grant/award (A): 11,000 (derivative) @ $0EDGAR
2024-04-034Lawley Lori D — Chief Financial OfficerGrant/award (A): 1,000 @ $2.84 · Tax withholding (F): 274 @ $2.84 · Grant/award (A): 12,000 (derivative) @ $0EDGAR
2024-04-034McKew John C. — Chief Scientific OfficerGrant/award (A): 2,000 @ $2.84 · Tax withholding (F): 1,036 @ $2.84 · Sale (S): 2,214 @ $2.77 · Grant/award (A): 16,000 (derivative) @ $0EDGAR
2024-04-034Hawkins Richard J — Chief Executive Officer, DirectorGrant/award (A): 4,500 @ $2.84 · Tax withholding (F): 1,522 @ $2.84 · Grant/award (A): 35,400 (derivative) @ $0EDGAR
2024-04-034Schuchart Aaron — Chief Business OfficerGrant/award (A): 1,000 @ $2.84 · Grant/award (A): 12,000 (derivative) @ $0EDGAR
2024-02-074McKew John C. — Chief Scientific OfficerSale (S): 438 @ $3.03EDGAR
2024-02-054McKew John C. — Chief Scientific OfficerTax withholding (F): 366 @ $3.01EDGAR
2024-02-054Hawkins Richard J — Chief Executive Officer, DirectorTax withholding (F): 690 @ $3.01EDGAR
2024-02-054Lawley Lori D — Chief Financial OfficerTax withholding (F): 215 @ $3.01EDGAR
2024-02-054Schuchart Aaron — Chief Business OfficerTax withholding (F): 202 @ $3.01EDGAR
2024-02-054POWERS BRADLEY J — General CounselTax withholding (F): 240 @ $3.01EDGAR
2023-08-034McKew John C. — Chief Scientific OfficerTax withholding (F): 1,593 @ $3.28 · Sale (S): 3,407 @ $3.21EDGAR
2023-08-034Lawley Lori D — Chief Financial OfficerTax withholding (F): 229 @ $3.28EDGAR
2023-05-124Zoth Lota S. — DirectorGrant/award (A): 3,345 (derivative) @ $0EDGAR
2023-05-124van Es-Johansson An — DirectorGrant/award (A): 3,345 (derivative) @ $0EDGAR
2023-05-124Raffin Thomas A. — DirectorGrant/award (A): 3,345 (derivative) @ $0EDGAR
2023-05-124McCracken Joseph S — DirectorGrant/award (A): 3,345 (derivative) @ $0EDGAR
2023-05-124LALANDE KEVIN M. — DirectorGrant/award (A): 3,345 (derivative) @ $0EDGAR
2023-05-124JOHNSON CHAD ALLEN — DirectorGrant/award (A): 3,345 (derivative) @ $0EDGAR
2023-04-044POWERS BRADLEY J — General CounselTax withholding (F): 342 @ $3.31EDGAR
2023-04-044McKew John C. — Chief Scientific OfficerTax withholding (F): 1,036 @ $3.31 · Sale (S): 2,214 @ $3.27EDGAR
2023-04-044Lawley Lori D — Chief Financial OfficerTax withholding (F): 274 @ $3.31EDGAR
2023-04-044Hawkins Richard J — Chief Executive Officer, DirectorTax withholding (F): 1,522 @ $3.31EDGAR
2023-02-034Lawley Lori D — Chief Financial OfficerGrant/award (A): 1,000 @ $3.52 · Tax withholding (F): 114 @ $3.52 · Grant/award (A): 12,000 (derivative) @ $0EDGAR
2023-02-034Karpf David B — Chief Medical OfficerGrant/award (A): 1,000 @ $3.52 · Tax withholding (F): 36 @ $3.52 · Grant/award (A): 12,000 (derivative) @ $0EDGAR
2023-02-034Hawkins Richard J — Chief Executive Officer, DirectorGrant/award (A): 4,500 @ $3.52 · Tax withholding (F): 416 @ $3.52 · Grant/award (A): 35,400 (derivative) @ $0EDGAR

Recent 8-K events — LUMOS PHARMA, INC.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2024-12-128-K1.02 — Termination of a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
3.03 — Material Modification to Rights of Security Holders
5.01 — Changes in Control of Registrant
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2024-11-258-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2024-10-238-K1.01 — Entry into a Material Definitive Agreement
2.02 — Results of Operations and Financial Condition
2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
9.01 — Financial Statements and Exhibits
EDGAR
2024-08-018-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2024-06-058-K5.07 — Submission of Matters to a Vote of Security Holders
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2024-05-158-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2024-04-188-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2024-03-208-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2024-03-078-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2024-01-048-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=LUMO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs